SeaSpine Competitors

SeaSpine (NASDAQ:SPNE) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. Comparatively, 36.0% of Inovio Pharmaceuticals shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 4.0% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Inovio Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

SeaSpine has higher revenue and earnings than Inovio Pharmaceuticals. SeaSpine is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Inovio Pharmaceuticals, as provided by MarketBeat.

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Inovio Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 94.95%. Given Inovio Pharmaceuticals' higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than SeaSpine.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares SeaSpine and Inovio Pharmaceuticals' net margins, return on equity and return on assets.

Summary

SeaSpine beats Inovio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. Comparatively, 96.9% of GenMark Diagnostics shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 3.3% of GenMark Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and GenMark Diagnostics' top-line revenue, earnings per share (EPS) and valuation.

SeaSpine has higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and GenMark Diagnostics, as provided by MarketBeat.

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. GenMark Diagnostics has a consensus price target of $22.0125, indicating a potential downside of 8.24%. Given SeaSpine's stronger consensus rating and higher possible upside, research analysts clearly believe SeaSpine is more favorable than GenMark Diagnostics.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500.

Profitability

This table compares SeaSpine and GenMark Diagnostics' net margins, return on equity and return on assets.

Summary

SeaSpine beats GenMark Diagnostics on 8 of the 14 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and Silk Road Medical (NASDAQ:SILK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 7.8% of Silk Road Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Silk Road Medical's top-line revenue, earnings per share (EPS) and valuation.

SeaSpine has higher revenue and earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Silk Road Medical, as provided by MarketBeat.

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Silk Road Medical has a consensus price target of $61.75, indicating a potential upside of 23.16%. Given Silk Road Medical's higher possible upside, analysts clearly believe Silk Road Medical is more favorable than SeaSpine.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares SeaSpine and Silk Road Medical's net margins, return on equity and return on assets.

Summary

SeaSpine beats Silk Road Medical on 10 of the 14 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. Comparatively, 31.8% of Alphatec shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 28.2% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Alphatec's top-line revenue, earnings per share (EPS) and valuation.

SeaSpine has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Alphatec, as provided by MarketBeat.

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Alphatec has a consensus price target of $15.4286, indicating a potential downside of 12.34%. Given SeaSpine's higher possible upside, research analysts clearly believe SeaSpine is more favorable than Alphatec.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.

Profitability

This table compares SeaSpine and Alphatec's net margins, return on equity and return on assets.

Summary

SeaSpine beats Alphatec on 8 of the 13 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and Luminex (NASDAQ:LMNX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. Comparatively, 88.1% of Luminex shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Comparatively, 9.4% of Luminex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Luminex's top-line revenue, earnings per share (EPS) and valuation.

Luminex has higher revenue and earnings than SeaSpine. Luminex is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Luminex, as provided by MarketBeat.

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Luminex has a consensus price target of $38.00, indicating a potential upside of 15.33%. Given Luminex's higher possible upside, analysts clearly believe Luminex is more favorable than SeaSpine.

Risk & Volatility

SeaSpine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares SeaSpine and Luminex's net margins, return on equity and return on assets.

Summary

Luminex beats SeaSpine on 10 of the 13 factors compared between the two stocks.

SeaSpine (NASDAQ:SPNE) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

76.7% of SeaSpine shares are held by institutional investors. 9.8% of SeaSpine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SeaSpine and Pulmonx's top-line revenue, earnings per share (EPS) and valuation.

Pulmonx has lower revenue, but higher earnings than SeaSpine.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaSpine and Pulmonx, as provided by MarketBeat.

SeaSpine presently has a consensus price target of $23.1667, indicating a potential upside of 5.59%. Pulmonx has a consensus price target of $58.00, indicating a potential upside of 33.39%. Given Pulmonx's higher possible upside, analysts clearly believe Pulmonx is more favorable than SeaSpine.

Profitability

This table compares SeaSpine and Pulmonx's net margins, return on equity and return on assets.

Summary

Pulmonx beats SeaSpine on 6 of the 11 factors compared between the two stocks.